StockDocs
Main Newswire Learn
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com

Lakewood-Amedex Gets Nasdaq Delisting Notice After Sub-$1 Bid Streak

Lakewood-Amedex Biotherapeutics said Nasdaq will delist its stock after 30 straight business days below $1, with trading suspended November 19 unless the company requests a hearing by November 17.

What happened

Lakewood-Amedex Biotherapeutics Inc., a pharmaceutical company based in University Park, Florida, said it received a letter dated November 10, 2026 from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying it that its common stock had closed below $1.00 per share for 30 consecutive business days, from September 29 through November 9, 2026.

The $1.00 level is the minimum bid price required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2), which the company calls the Bid Price Rule. Nasdaq's staff determined to delist the company's securities, according to the 8-K filed November 16, 2026.

The company said trading of its common stock will be suspended at the opening of business on November 19, 2026, and that Nasdaq will file a Form 25-NSE with the SEC to remove the securities from listing and registration, unless the company requests a hearing by November 17, 2026.

Lakewood-Amedex said it intends to timely request a hearing before a Nasdaq Hearings Panel, which would stay the suspension and the Form 25-NSE filing pending the panel's decision. At the hearing the company intends to present a plan to regain compliance that may include a reverse stock split. The company said there can be no assurance the panel will grant continued listing or that it will regain compliance.

The shares closed at $0.22 on the event date, down 21.43% from the prior close of $0.28, according to the price data.

Why the usual cure period was not available

Nasdaq's Bid Price Rule normally gives a company 180 calendar days to regain compliance. The company said it is not eligible for that compliance period because it effected a 1-for-10 reverse stock split on June 22, 2026, within the prior one-year period.

The filing cites Nasdaq Listing Rule 5810(c)(3)(A)(iv) as the provision that bars the compliance period in this circumstance. The 8-K does not state why the company's shares remained below $1.00 after the June split.

What this means

An 8-K is the form a U.S. public company files with the SEC to report material events between quarterly reports. Item 3.01 of the form is specifically for notice of delisting or failure to satisfy a continued listing rule, which is the item Lakewood-Amedex checked here.

A reverse stock split combines several existing shares into one. In a 1-for-10 split, every ten shares become one, and the share price rises roughly tenfold while the number of shares outstanding falls. Companies use it to lift a share price above a minimum like Nasdaq's $1.00. This filing says the company completed one in June 2026, and the delisting notice shows the bid price was again below $1.00 for 30 straight business days this fall.

A Form 25-NSE is the notice Nasdaq files with the SEC to strike a security from its listing and from registration under Section 12(b) of the Securities Exchange Act. It is different from a Form 25 filed for debt securities approaching maturity: this one would remove common stock from the exchange entirely.

A hearing request buys time rather than compliance. The company's own filing says the request stays the suspension and the Form 25-NSE filing until the panel rules. A Nasdaq Hearings Panel can grant continued listing, often on conditions such as reaching a specified bid price within a set period. The filing does not say what those conditions, if any, would be, and the company states there is no assurance the panel will grant the request.

The company's stated plan at the hearing may include another reverse stock split. The filing does not identify any other measure the company would propose.

About the company

Lakewood-Amedex Biotherapeutics is incorporated in Nevada and listed on Nasdaq under the ticker LABT, with par value $0.0001 per share. In its 8-K it identifies its business under the SEC classification "Pharmaceutical Preparations." It is an emerging growth company as defined under SEC rules. The filing does not describe its product pipeline or financial condition.

Sources

Information summarized by AI from the sources listed above. May contain errors — informational only, not investment advice.